Comparative Bioavailability and Tolerability of a Single 2-mg Dose of 2 Repaglinide Tablet Formulations in Fasting, Healthy Chinese Male Volunteers: An Open-Label, Randomized-Sequence, 2-Period Crossover Study()

BACKGROUND: Repaglinide, an oral insulin secretagogue, was the first meglitinide analogue to be approved for use in patients with type 2 diabetes mellitus. OBJECTIVE: In our study, the bioavailability and tolerability of the proposed generic formulation with the established reference formulation of...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhai, Xue-jia, Hu, Kai, Chen, Fen, Lu, Yong-ning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2013
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3898188/
https://www.ncbi.nlm.nih.gov/pubmed/24465043
http://dx.doi.org/10.1016/j.curtheres.2013.08.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3898188/
https://www.ncbi.nlm.nih.gov/pubmed/24465043
http://dx.doi.org/10.1016/j.curtheres.2013.08.001

Ejemplares similares